^
1d
BRAF p.V600E Mutation in Mixed Odontogenic Tumors and Its Clinical Correlation: A Systematic Review and Meta-Analysis. (PubMed, Int Dent J)
Its presence in a substantial portion of AFO/AFD/DO, together with their larger size compared to OD, could support a neoplastic nature in at least a subset of these lesions, though a hamartomatous DO may exist. Further investigation and clinical correlation remain essential to distinguish these entities.
Retrospective data • Journal
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600
2d
ADVL1823: Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia (clinicaltrials.gov)
P2, N=33, Active, not recruiting, Children's Oncology Group | Trial completion date: Mar 2026 --> Jul 2027
Trial completion date
|
NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • ETV6 (ETS Variant Transcription Factor 6)
|
Vitrakvi (larotrectinib)
4d
[68Ga]Ga-DOTA-CEND1: A Novel PET Cyclic Peptide Tracer for Noninvasive Imaging of Neuropilin-1 Expression in Pan-Tumors. (PubMed, Mol Pharm)
Micro PET/CT at 1 h postinjection revealed significantly higher tumor uptake in NRP-1 positive tumor models than in the NRP-1 negative tumor model, while coinjection with nonradioactive CEND-1 significantly reduced tumor uptake, and tumor-to-muscle ratios aligned with NRP-1 expression levels, confirming the specificity and sensitivity of the radiotracer. As the first PET cyclic peptide radiotracer, [68Ga]Ga-DOTA-CEND1 holds great potential for noninvasively detecting NRP-1 expression across tumor types, optimizing NRP-1 targeted therapy, and evaluating therapeutic responses.
Journal • Pan tumor
|
NRP1 (Neuropilin 1)
4d
Primary Bone Sclerosing Epithelioid Fibrosarcoma: A Case Report and Literature Review. (PubMed, Cureus)
Timely identification and precise diagnosis with specific immunohistochemistry are crucial in guiding an appropriate treatment strategy. Our analysis of 38 cases, including our case, showed a male predominance, spinal involvement, and a high MUC4 positivity rate, reinforcing its role as a key diagnostic marker.
Journal
|
MUC4 (Mucin 4, Cell Surface Associated)
6d
Importance of SUMOylation Consensus Sequence of MAFK in Regulating EMT, Tumor Growth, Stemness, and Drug Resistance. (PubMed, Cancer Sci)
In this study, we focused on SUMOylation and investigated the importance of the SUMOylation consensus sequence in MAFK for MAFK-induced EMT, cellular migration and invasion, tumor and sphere formation, acquisition of stem-like properties, and drug resistance against doxorubicin by using the non-SUMOylation mimic mutant. Additionally, our results suggest that these findings depend on the expression of ATP-binding cassette (ABC) transporter 2 (ABCG2).
Journal
|
ABCG2 (ATP Binding Cassette Subfamily G Member 2) • MAFB (MAF BZIP Transcription Factor B)
|
doxorubicin hydrochloride
8d
Cardamonin Inhibits the Nuclear Translocation and DNA Binding of RelA in the Tumor Necrosis Factor-α-Induced NF-κB Signaling Pathway in Human Lung Adenocarcinoma A549 Cells. (PubMed, Molecules)
Mutations in these interaction sites abrogated the nuclear translocation of RelA in response to a TNF-α stimulation. The present results demonstrate that cardamonin inhibited the nuclear translocation of RelA and its DNA binding in the NF-κB signaling pathway in response to a TNF-α stimulation.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • ICAM1 (Intercellular adhesion molecule 1) • NFKBIA (NFKB Inhibitor Alpha 2)
8d
Functional analysis of AKT1 knockout in fibrosarcoma cells using CRISPR/Cas9 technology. (PubMed, J Hum Genet)
The expression levels of mTOR, BCL-2, and FOXO1 were significantly altered in the KO cells compared to normal cells. These findings highlight the impact of AKT1 disruption on signaling pathways and provide fundamental insights into the regulatory role of the AKT1 gene.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • mTOR (Mechanistic target of rapamycin kinase)
11d
Mutation of the Collagen Type 1α Gene in Human Fibrosarcoma Cells Using the CRISPR/Cas9 System. (PubMed, Biochemistry)
Moreover, the expression levels of MMP-1, MMP-2, MMP-9, AKT, and p-mTOR were reduced in the edited cells. These findings could provide a crucial clue in elucidating the close relationship between collagen production and senescence.
Journal
|
MDM2 (E3 ubiquitin protein ligase) • MMP2 (Matrix metallopeptidase 2) • CDK2 (Cyclin-dependent kinase 2) • COL1A1 (Collagen Type I Alpha 1 Chain) • MMP9 (Matrix metallopeptidase 9) • CDK1 (Cyclin-dependent kinase 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • MMP1 (Matrix metallopeptidase 1)
16d
Multifaceted anticancer activity of nafamostat mesylate in human fibrosarcoma: first evidence of mitochondrial apoptosis and suppressed MMP-2/-9 mRNA expression. (PubMed, BMC Pharmacol Toxicol)
This study provides the first evidence that nafamostat mesylate exerts multifaceted anticancer effects in HT1080 fibrosarcoma cells, targeting proliferation, migration, apoptosis, and invasion. These findings support the potential repurposing of nafamostat mesylate as a therapeutic agent for fibrosarcoma and warrant further preclinical investigations to evaluate its translational applicability.
Journal
|
MMP2 (Matrix metallopeptidase 2) • MMP9 (Matrix metallopeptidase 9) • ANXA5 (Annexin A5)
|
nafamostat
21d
Dual faces of angiogenesis: Mechanisms and therapeutic applications. (PubMed, Biochim Biophys Acta Rev Cancer)
We compared malignant and non-malignant angiogenesis at the molecular and clinical levels, critically appraising therapies, from VEGF antibodies and multitarget TKIs (tyrosine kinase inhibitors) to pro-angiogenic growth factors and drug-delivery platforms, and their respective biomarkers (Ang-2, soluble VEGFR2, VEGF isoform ratios). By explicitly linking pathway mechanics to therapeutic choice, dosing, and biomarker-guided selection, this review provides a comprehensive roadmap for tailoring angiogenesis-targeted interventions, either to restrain pathological neovascularization in cancer or to promote reparative vessel growth in ischemic and degenerative disease.
Review • Journal
|
MET (MET proto-oncogene, receptor tyrosine kinase) • KDR (Kinase insert domain receptor) • FGF2 (Fibroblast Growth Factor 2)
22d
AMPK Limits MNNG-Induced Parthanatos by Inhibiting BH3-Only Protein Bim. (PubMed, Int J Mol Sci)
These observations suggest that the AMPK signaling pathways activated by PARP-1-dependent ATP depletion limit parthanatos by blocking the Bim upregulation triggering Bim-mediated parthanatos. Thus, our results demonstrate a novel relationship between AMPK and parthanatos, which may provide insights into the physiological roles of parthanatos.
Journal • PARP Biomarker • IO biomarker
|
BCL2L11 (BCL2 Like 11) • AMPK (Protein Kinase AMP-Activated Catalytic Subunit Alpha 1)